ARTICLE | Management Tracks
Park joins HanAll as co-CEO
Plus: Lucy hires Winrow as CSO and an update from Duke Street
March 29, 2023 11:44 PM UTC
HanAll Biopharma Co. Ltd. (KSE:009420) named Su-jin Park as co-CEO, to work alongside the company’s other co-CEO, Sean Jeong. Park’s focus will be on strengthening the company’s domestic pharmaceutical business and growing its sales; Jeong will continue to lead R&D. HanAll Biopharma is developing a pipeline of immunology and oncology products of which the most advanced are HL036 and HL161; they are in Phase III testing to treat dry eye disease and myasthenia gravis, respectively.
Mitochondrial dysfunction company Lucy Therapeutics Inc. hired Christopher Winrow as CSO. Winrow was VP and head of translational medicine at Cyclerion Therapeutics Inc. (NASDAQ:CYCN)...